

Contents

Dedication	v
Preface	vii

PART I. VIRAL INFECTIONS

CHAPTER 1

CYTOMEGALOVIRUS

1. Introduction	3
2. HCMV Infection in Immunocompromised Hosts	4
3. Studies on Therapeutics	5
3.1. Ganciclovir	5
3.1.1. Toxicity of Ganciclovir	5
3.2. Foscarnet	6
3.2.1. Toxicity of Foscarnet	6
3.3. Cidofovir	7
3.4. Fomivirsen	7
3.5. Valaciclovir	8
4. Treatment of HCMV Infections	8
4.1. Management of HCMV Disease in AIDS Patients	8
4.2. Management of HCMV Disease in Solid Organ and Bone-Marrow Transplant Recipients	10
5. Prophylaxis and Maintenance Therapy of HCMV Disease	11
6. Ganciclovir Versus Foscarnet in the Treatment of HCMV Infection	13
7. Effects of HAART on HCMV Disease	13
8. Application of Immunotherapy for HCMV Infections	14

CHAPTER 2

VARICELLA-ZOSTER VIRUS (HERPES ZOSTER) INFECTIONS

1. Introduction	23
2. Studies on Therapeutics	24
2.1. Acyclovir	24
2.2. Famciclovir	24
2.3. Sorivudine	25
3. Treatment of Varicella-Zoster Infections	25
3.1. Herpes Zoster in Organ-Transplant Recipients	26
3.2. Herpes Zoster in HIV-Infected Patients	27
3.3. Management of Drug-Resistant Varicella-Zoster Virus Infections	27

3.4. Varicella-Zoster Virus Pneumonitis	27
3.5. Herpes-Zoster Ophthalmicus	27

CHAPTER 3

HERPES SIMPLEX VIRUS

1. Introduction	33
2. Treatment of Herpes Simplex Virus Infections	34
2.1. Vidarabine	35
2.2. Acyclovir (Aciclovir)	36
2.3. Valaciclovir	37
2.4. Famciclovir/Penciclovir	38
2.5. Foscarnet	39
2.6. Cidofovir	40
2.7. Brivudine (Bromovinyldeoxyuridine, BVDU)	41
2.8. Drug-Resistant Herpes Simplex Virus and Evolving Therapeutic Strategies	41
3. Prophylaxis of Herpesvirus Infections	43

PART II. BACTERIAL INFECTIONS

CHAPTER 4

NOCARDIA SPP.

1. Introduction	55
2. Nocardiosis in Immunocompromised Hosts	55
2.1. Nocardiosis in HIV-Positive Patients	56
2.2. Co-Infections With Other Pathogens	57
3. Treatment of Nocardiosis	57
3.1. Sulfonamides	58
3.2. Sulfonamide-Trimethoprim Combinations	58
3.3. Antibiotics	59
3.4. Acquired Drug Resistance of <i>Nocardia</i> spp.	60

CHAPTER 5

OERSKOVIA SSP.

1. Introduction	71
2. Treatment of <i>Oerskovia</i> Infections	71

CHAPTER 6

RHODOCOCCUS EQUI

1. Introduction	73
2. Treatment of <i>Rhodococcus equi</i> Infection	74

CHAPTER 7

TSUKAMURELLA SSP.

1. Introduction	79
2. Treatment of <i>Tsukamurella</i> Infections	79

CHAPTER 8

MYCOBACTERIUM TUBERCULOSIS

1. Introduction	81
2. <i>Mycobacterium tuberculosis</i> Infections in AIDS Patients	81
3. Evolution of Therapies and Treatment of <i>Mycobacterium</i> <i>tuberculosis</i> Infections	82
3.1. Drug Interactions in HIV-Infected Patients	83
3.2. Drug Resistance in Tuberculosis	83
3.3. Highly Active Antiretroviral Therapy (HAART) and Mycobacterial Infections in HIV-Infected Patients	84
3.4. Prophylaxis of Tuberculosis in HIV-Infected Patients	85
3.5. Adjunctive Immunotherapy of Tuberculosis	85
3.6. Vaccine Development Against Tuberculosis	85

CHAPTER 9

MYCOBACTERIUM BOVIS

1. Introduction	91
2. Treatment of <i>Mycobacterium bovis</i> Infections	92
3. BCG Vector-Based Vaccines in Immunotherapy Against HIV Infection	92

CHAPTER 10

NONTUBERCULOUS MYCOBACTERIAL INFECTIONS

1. Introduction	95
2. Nontuberculous Mycobacterial Infections and AIDS	96
3. <i>Mycobacterium avium</i> Complex (MAC)	96
3.1. Introduction	96
3.2. Treatment of <i>Mycobacterium avium-intracellulare</i> Complex (MAC) Infections	97
3.2.1. Immunotherapy of MAC Infections	103
3.2.2. Prophylaxis of <i>Mycobacterium avium-intracellulare</i> Infections in AIDS Patients	103
3.2.3. MAC Infections and Highly Active Antiretroviral Therapy (HAART)	107
4. <i>Mycobacterium kansasii</i>	107
4.1. Introduction	107
4.2. Treatment of <i>M. kansasii</i> Infections	108
5. <i>Mycobacterium xenopi</i>	110
5.1. Introduction	110
5.2. Treatment of <i>M. xenopi</i> Infections	111
6. <i>Mycobacterium haemophilum</i>	112
6.1. Treatment of <i>M. haemophilum</i> Infections	112
7. <i>Mycobacterium genavense</i>	114

CHAPTER 11

LISTERIA MONOCYTOGENES

1. Introduction 129
2. Listeriosis in AIDS Patients 130
3. Treatment of Listeriosis 131

CHAPTER 12

GASTROINTESTINAL INFECTIONS IN THE IMMUNOCOMPROMISED HOST

1. Introduction 135
2. Therapeutic Strategies for Enteric Infections 136
 - 2.1. Prevention of Enteric Infections 137

PART III. PARASITIC INFECTIONS

CHAPTER 13

CRYPTOSPORIDIUM SPP.

1. Introduction 143
2. Treatment of Cryptosporidiosis 144
 - 2.1. Macrolide Antibiotics 144
 - 2.2. Paromomycin 145
 - 2.3. Rifaximin 146
 - 2.4. Nitazoxanide (NTZ, Cryptaz) 146
 - 2.5. Somatostatin and Analogues 147
 - 2.6. Immunotherapy of Cryptosporidiosis 148
 - 2.7. Antiretroviral Therapies and Cryptosporidiosis 150
 - 2.8. Alternative Therapies for Cryptosporidiosis 150

CHAPTER 14

ISOSPORA SPP.

1. Introduction 159
2. Treatment of Isosporiasis 160

CHAPTER 15

TOXOPLASMA GONDII

1. Introduction 163
2. Treatment of Toxoplasmosis 164
 - 2.1. Pyrimethamine-Sulfonamide Combinations 165
 - 2.1.1. Acute Renal Failure to Sulfadiazine Therapy
in AIDS Patients 167
 - 2.1.2. Adverse Cutaneous Reactions to Pyrimethamine
Combinations in AIDS Patients 167
 - 2.2. Trimethoprim-Sulfonamide Combinations 168
 - 2.3. Antibiotic Therapy of Toxoplasmosis 168
 - 2.3.1. Spiramycin 168
 - 2.3.2. Clindamycin and Clindamycin-Pyrimethamine
Combinations 169
 - 2.3.3. Clarithromycin 170

2.3.4. Azithromycin	171
2.3.5. Doxycycline	171
2.4. Atovaquone	171
2.5. Trimetrexate	172
2.6. Management of Ocular Toxoplasmosis	172
3. Prophylaxis of Cerebral Toxoplasmosis	173
4. Prophylaxis Against Toxoplasmosis and HAART in HIV-Infected Patients	175
5. Immunotherapy of Toxoplasmosis	175

CHAPTER 16

MICROSPORIDIA

1. Introduction	183
2. <i>Enterocytozoon bienersi</i>	184
3. <i>Encephalitozoon</i> spp.	185
4. <i>Pleistophora</i> spp.	185
5. <i>Trachipleistophora hominis</i>	185
6. <i>Nosema</i> spp.	185
7. <i>Brachiola vesicularum</i>	186
8. Treatment of Microsporidiosis	186

CHAPTER 17

STRONGYLOIDES STERCORALIS

1. Introduction	195
2. Strongyloidiasis as Opportunistic Infection in Immunocompromised Hosts	195
3. Corticosteroid Therapy as a Predisposing Factor for Strongyloidiasis	197
4. Treatment of Strongyloidiasis	197
4.1. Comparative Studies	198

CHAPTER 18

CYCLOSPORA SPP.

1. Introduction	205
2. Treatment of Cyclosporiasis	206

PART IV. FUNGAL INFECTIONS

CHAPTER 19

CRYPTOCOCCUS NEOFORMANS

1. Introduction	213
2. Treatment of Cryptococcosis	214
2.1. Amphotericin B	216
2.1.1. Toxicity of Amphotericin B	218
2.2. Combinations of Amphotericin B with 5-Fluorocytosine and Other Drugs	218
2.2.1. Toxicity of Amphotericin B-5-Fluorocytosine Combinations	220

2.3. 5-Fluorocytosine (5-FC)	221
2.4. Azole Derivatives	221
2.4.1. Miconazole	221
2.4.2. Ketoconazole	222
2.4.3. Fluconazole	222
2.4.4. Itraconazole	225
3. Prophylaxis and Maintenance Therapy of Cryptococcosis	226
4. <i>Cryptococcus neoformans</i> var. <i>gattii</i>	226
5. <i>Cryptococcus albidus</i>	227
6. <i>Cryptococcus laurentii</i>	227

CHAPTER 20

CANDIDA ALBICANS

1. Introduction	239
2. Human Candidiasis	239
2.1. Candidal Infections in HIV-Infected Patients	240
3. Treatment of Candidiasis	241
3.1. Cutaneous Candidiasis	241
3.2. Chronic Mucocutaneous Candidiasis	242
3.3. Candidal Onychomycosis	242
3.4. Oropharyngeal and Esophageal Candidiasis	242
3.5. Systemic Candidiasis	245
3.5.1. Endogenous (Hematogenous) Candidal Endophthalmitis (HCE)	248
3.5.2. Candidal Meningitis	249
3.5.3. Candidal Endocarditis	249
3.5.4. Vulvovaginal Candidiasis	250
3.5.5. Urinary and Peritoneal Candidiasis	251
3.5.6. Candidal Arthritis and Osteomyelitis	253
3.5.7. Neonatal Candidiasis	253
4. Azole Drug Resistance and Refractory Candidiasis	255
5. HAART Therapy and Candidiasis	256
6. Drug Activities and <i>Candida</i> Virulence	256
7. Prophylaxis of <i>Candida</i> Infections	257

CHAPTER 21

EMERGING CANDIDA SPP. INFECTIONS

1. Introduction	269
2. <i>Candida glabrata</i>	269
2.1. Treatment of <i>C. glabrata</i> Infections	270
2.1.1. Fluconazole in the Treatment of <i>C. glabrata</i> Infections	271
2.1.2. <i>C. glabrata</i> -Induced Vulvovaginal Candidiasis	271
2.2. <i>Candida glabrata</i> Prophylaxis	272
3. <i>Candida krusei</i>	273
3.1. Prophylaxis Against <i>C. krusei</i> Infections and Azole Resistance	273

4. <i>Candida lusitanae</i>	274
5. <i>Candida dubliniensis</i>	275
5.1. Molecular and Phenotypic Characterization of <i>C. dubliniensis</i>	276
5.2. Treatment of <i>C. dubliniensis</i> Candidiasis	276
5.2.1. <i>C. dubliniensis</i> Resistance to Fluconazole	277
6. <i>Candida rugosa</i>	277
7. <i>Candida zeylanoides</i>	278
8. <i>Candida famata</i>	278
9. <i>Candida guilliermondii</i>	279
10. <i>Candida norvegensis</i>	279
11. <i>Candida lipolytica</i>	280
12.. <i>Candida viswanathii</i>	280
13. <i>Candida haemulonii</i>	280
14. <i>Pichia jadinii</i> (<i>Candida utilis</i>)	281
15. <i>Candida ciferrii</i>	281
CHAPTER 22	
TRICHOSPORON BEIGELII	
1. Introduction	291
2. Treatment of Trichosporonosis	292
3. <i>Blastoschizomyces capitatus</i>	293
3.1 Treatment of <i>B. capitatus</i> Infections	294
CHAPTER 23	
RHODOTORULA SPP.	
1. Introduction	299
2. Treatment of <i>Rhodotorula</i> Infections	299
CHAPTER 24	
HANSENULA (PICHIA) SPP.	
1. Introduction	303
2. Treatment of <i>Hansenula</i> spp. Infections	303
CHAPTER 25	
DEMATIACEOUS FUNGAL INFECTIONS: PHAEOHYPHOMYCOSIS AND CHROMOBLASTOMYCOSIS	
1. Introduction	307
2. Phaeohyphomycosis	308
2.1. Treatment of Phaeohyphomycosis	309
2.1.1. <i>Bipolaris</i> spp. and <i>Exserohilum</i> spp. Phaeohyphomycosis	309
2.1.2. <i>Exophiala</i> (<i>Wangiella</i>) <i>dermatitidis</i> and <i>Exophiala</i> spp. Phaeohyphomycosis	311
2.1.3. <i>Alternaria</i> spp. Phaeohyphomycosis	313
2.1.3.1. THERAPY OF ALTERNARIOSIS	314
2.1.4. <i>Phaeosclera dematioides</i> Phaeohyphomycosis	316

2.1.5. <i>Curvularia</i> spp. Phaeohyphomycosis	316
2.1.6. <i>Ochroconis gallopava</i> Phaeohyphomycosis	318
2.1.7. <i>Phialophora</i> spp. Phaeohyphomycosis	319
2.1.8. <i>Phaeoacremonium</i> spp. Phaeohyphomycosis	320
2.1.9. <i>Hormonema dermatioides</i> Phaeohyphomycosis	320
2.1.10. <i>Aureobasidium</i> spp. Phaeohyphomycosis	320
2.1.11. <i>Colletotrichum</i> spp. Phaeohyphomycosis	321
2.1.12. <i>Mycocleptodiscus indicus</i> Phaeohyphomycosis	321
2.1.13. <i>Phoma</i> spp. Phaeohyphomycosis	321
2.1.14. <i>Pleurophomopsis</i> spp. Phaeohyphomycosis	322
2.1.15. <i>Pyrenochaeta</i> spp. Phaeohyphomycosis	322
2.1.16. <i>Geniculosporium</i> spp. Phaeohyphomycosis	322
2.1.17. <i>Veronaea bothryosa</i> Phaeohyphomycosis	322
2.2. Cerebral Phaeohyphomycosis	322
2.2.1. <i>Nodulisporium</i> spp. Phaeohyphomycosis	323
2.2.2. <i>Scopulariopsis</i> spp. Phaeohyphomycosis	323
2.2.3. <i>Ramichloridium</i> spp. Phaeohyphomycosis	323
2.2.4. <i>Cladophialophora</i> spp. Phaeohyphomycosis	323
2.2.4.1. <i>CLADOPHIALOPHORA BANTIANA</i> (<i>XYLOHYPHA BANTIANA</i> , <i>CLADOSPORIUM BANTIANUM</i>)	324
2.3. Fungal Peritonitis in Continuing Ambulatory Peritoneal Dialysis (CAPD)	325
3. Chromoblastomycosis	326
CHAPTER 26	
HYALOHYPHOMYCOSIS	
1. Introduction	343
2. <i>Pseudallescheria boydii</i> Infections	343
3. <i>Scedosporium</i> spp. Infections	347
3.1. <i>Scedosporium apiospermum</i>	347
3.2. <i>Scedosporium prolificans</i> (<i>S. inflatum</i>)	348
4. <i>Fusarium</i> spp. Infections	349
4.1. Treatment of Fusariosis	350
4.2. <i>Fusarium napiforme</i>	353
5. <i>Phialemonium</i> spp. Infections	354
6. <i>Acremonium</i> spp. Infections	354
7. <i>Scopulariopsis</i> spp. Infections	355
7.1. <i>Scopulariopsis brevicaulis</i>	355
7.2. <i>Scopulariopsis acremonium</i>	357
8. <i>Microascus</i> spp. Infections	357
8.1. <i>Microascus cinereus</i>	357
8.2. <i>Microascus cirrosis</i>	357
9. <i>Paecilomyces</i> spp. Infections	357
9.1. Treatment of <i>Paecilomyces</i> Infections	359
9.1.1. <i>Paecilomyces lilacinus</i>	359

9.1.2. <i>Paecilomyces variotii</i>	360
9.1.3. Post-Transplantation Therapy of <i>Paecilomyces</i> Infections	360
10. <i>Acrophialophora fusispora</i> Infections	360
11. <i>Engyodontium album</i> Infections	361
12. <i>Beauveria bassiana</i> Infections	361
13. Non- <i>Candida</i> Mycoses After Solid Organ and Bone-Marrow Transplantations	362
14. Pharmacokinetic Interactions of Cyclosporin A with Azole Antimycotics	364

CHAPTER 27

HISTOPLASMA *SPP.*

1. Introduction	383
2. Evolution of Therapies and Treatment of Histoplasmosis	383
2.1. Prophylaxis in Histoplasmosis	386
2.2. Histoplasmosis in AIDS Patients	386
2.3. Histoplasmosis in Transplant Recipients	389
2.4. Skin Manifestations of Histoplasmosis	389
2.5. Gastrointestinal Histoplasmosis	390
2.6. Orofacial Manifestations of Histoplasmosis	390
2.7. Ocular Histoplasmosis	391
2.8. Rheumatic Manifestations of Histoplasmosis	391
2.9. Mediastinal Histoplasmosis	392
2.10. Pulmonary Histoplasmosis and Pleural Effusions	393
2.11. Histoplasmosis of the Central Nervous System	393
2.12. Adrenal Histoplasmosis	394
2.13. Musculoskeletal Histoplasmosis	394
2.14. Histoplasmosis of the Thyroid	394
2.15. Genitourinary Histoplasmosis	394
2.15.1. Prostatic Histoplasmosis	395
2.16. Childhood Histoplasmosis	395
3. Host Immune Defense Against Histoplasmosis	396

CHAPTER 28

AFRICAN HISTOPLASMOSIS

1. Introduction	409
2. Management of African Histoplasmosis and Evolution of Therapies	409

CHAPTER 29

BLASTOMYCES DERMATITIDIS

1. Introduction	413
2. African Blastomycosis	414
3. Role of Host Immune Response Against <i>Blastomyces dermatitidis</i>	415
4. Evolution of Therapies and Treatment of Blastomycosis	415

4.1. Amphotericin B	415
4.2. Azole Derivatives	418
4.2.1. Ketoconazole	418
4.2.2. Itraconazole	419
4.2.3. Fluconazole	420
4.2.4. Miconazole	420
4.3. Treatment of Adult Respiratory Distress Syndrome (ARDS) Secondary to Blastomycosis	420

CHAPTER 30

ASPERGILLUS SPP.

1. Introduction	429
1.1. <i>Aspergillus</i> -Related Spondylodiscitis	431
2. Host Immune Response to Aspergillosis	431
3. Therapies and Treatment of Aspergillosis	432
3.1. Amphotericin B	432
3.1.1. Liposome-Encapsulated and Lipid-Based Formulations of Amphotericin B	434
3.1.2. Routes of Administration	436
3.1.3. Combinations of Amphotericin B With Other Drugs	437
3.2. Azole Derivatives	439
3.2.1. Clotrimazole	439
3.2.2. Miconazole	439
3.2.3. Ketoconazole	441
3.2.4. Fluconazole	441
3.2.5. Itraconazole	441
3.3. Terbinafine	444
3.4. Caspofungin	444
3.5. Sodium (Potassium) Iodide Therapy of Aspergilloma	445
3.6. Therapy of Allergic Bronchopulmonary Aspergillosis (ABPA)	445
3.7. Therapy of <i>Aspergillus</i> -Induced Otomycosis	446
3.8. Therapy of <i>Aspergillus</i> -Induced Onychomycosis	447
4. Prophylaxis Against Aspergillosis	447
5. <i>Aspergillus chevalieri</i>	448

CHAPTER 31

COCCIDIOIDES IMMITIS

1. Introduction	461
2. Immune Responses to Human Coccidioidomycosis	462
3. Evolution of Therapies and Treatment of Coccidioidomycosis	462
3.1. Coccidioidomycosis in Immunocompromised Hosts and AIDS Patients	464
3.2. Cutaneous Manifestations	466
3.3. Coccidioidomycosis in Pregnancy and Early Infancy	466
3.4. Coccidioidomycosis in Transplant Recipients	467

3.4.1. Cardiac Transplant Recipients	467
3.4.2. Renal Transplant Recipients	468
3.4.3. Liver Transplant Recipients	468
3.4.4. Bone-Marrow Transplant Recipients	468
3.5. Ocular Coccidioidomycosis	469
3.6. Acute Respiratory Failure	469
3.7. Coccidioidal Peritonitis and Gastrointestinal Dissemination	469
3.8. Coccidioidal Infections of Bones and Joints	470
3.9. Genitourinary Coccidioidomycosis	471
3.9.1. Coccidioidomycosis of the Prostate	471
3.9.2. Infection of Intrascrotal Contents With or Without Prostatic Involvement	471
3.9.3. Bladder Involvement	471
3.9.4. Other Coccidioidal Genitourinary Involvement	471
3.10. Coccidioidal Infection of Arterial Prosthesis	471
3.11. Coccidioidal Infections of CNS	471
4. Prophylaxis of Coccidioidomycosis	472
5. Vaccine Studies in Humans	472

CHAPTER 32

PARACOCCIDIOIDES BRASILIENSIS

1. Introduction	483
2. Host Immune Response to Paracoccidioidomycosis	484
3. Paracoccidioidomycosis in the Immunocompromised Host	485
4. Treatment of Paracoccidioidomycosis	486
4.1. Sulfonamides	486
4.2. Amphotericin B	486
4.3. Azole Derivatives	487
4.3.1. Adrenocortical Dysfunction in Paracoccidioidomycosis and Azole Therapy	488
4.4. Immunostimulants in the Treatment of Paracoccidioidomycosis	489

CHAPTER 33

PENICILLIUM MARNEFFEI

1. Introduction	495
2. Treatment of <i>Penicillium marneffei</i> Infections	496
3. Prophylaxis and Maintenance Therapy Against <i>Penicillium marneffei</i>	497

CHAPTER 34

ZYGOMYCOSIS (*MUCORMYCOSIS*, *PHYCOMYCOSIS*)

1. Introduction	501
2. Treatment of Zygomycosis	502
2.1. Amphotericin B Therapy	502

CHAPTER 35

PNEUMOCYSTIS CARINII

1. Introduction	507
2. Genetic Diversity of <i>P. carinii</i> and Clinical Outcome	508
3. Subclinical <i>P. carinii</i> Infection	508
4. Atypical <i>P. carinii</i> Pulmonary Disease	508
5. Extrapulmonary <i>P. carinii</i> Infection	508
6. <i>P. carinii</i> Pneumonia Secondary to Methotrexate-Treated Rheumatoid Arthritis	509
7. Evolution of Therapies and Treatment of <i>P. carinii</i> Pneumonia	510
7.1. Adjunctive Corticosteroid Therapy for <i>P. carinii</i> Pneumonia	514
7.2. Toxicity of Sulfonamides	515
7.3. Toxicity of Pentamidine	516
7.4. Toxicity of Dapsone	516
7.5. Synergistic Anti- <i>P. carinii</i> Activity	517
8. Prophylaxis Against <i>P. carinii</i> Pneumonia	517
Index	535



<http://www.springer.com/978-1-58829-009-0>

Opportunistic Infections

Treatment and Prophylaxis

Georgiev, V.S.

2003, XX, 545 p., Hardcover

ISBN: 978-1-58829-009-0

A product of Humana Press